Results 131 to 140 of about 5,463 (146)

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

New England Journal of Medicine, 2017
Robert Marcus, Andrew J Davies, Wolfram Klapper   +2 more
exaly  

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

New England Journal of Medicine, 2019
Othman Al-Sawaf, Anna-Maria Fink, Stephen Opat   +2 more
exaly  

Obinutuzumab

Drugs of the Future, 2011
null Karlin, L., null Salles, G.
openaire   +1 more source

Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia

Cancer Discovery, 2020
Jennifer A Woyach, James S Blachly, Barbara L Andersen   +2 more
exaly  

Obinutuzumab

Reactions Weekly, 2014
openaire   +1 more source

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

New England Journal of Medicine, 2014
Javier De La Serna, Stephen Opat, Stephan Stilgenbauer   +2 more
exaly  

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Lancet Oncology, The, 2019
Carol Moreno, Richard F Greil, Fatih Demirkan   +2 more
exaly  

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

Lancet Oncology, The, 2016
Laurie H Sehn, Jiri Mayer, Marek Trneny
exaly  

Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production

OncoImmunology, 2017
Cristina Capuano, Chiara Pighi, Rosa Molfetta   +2 more
exaly  

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

Blood, 2012
Laurie H Sehn, Randy D Gascoyne
exaly